Skip to main content

Advertisement

SpringerLink
Log in

Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Colorectal cancer is the second leading cause of cancer death in industrialized nations, accounting for 10 % of the total cancer burden with an individual lifetime risk of ~6 % in the USA (Siegel et al. in CA Cancer J Clin 62:9–29, 2014, American Cancer Society in Colorectal cancer facts and figures 2011–2013. American Cancer Society, Atlanta, 2011, Siegel et al. in CA Cancer J Clin 61:212–236, 2011). Although numerous screening methods have been incorporated into guidelines for colorectal cancer screening, no guideline includes a noninvasive blood-based test as a recommended option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;62:9–29.

    Article  Google Scholar 

  2. American Cancer Society. Colorectal cancer facts and figures 2011–2013. Atlanta: American Cancer Society; 2011.

    Google Scholar 

  3. Siegel R, Ward E, Brawley O, Jemal A, Cancer statistics. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–236.

    Article  PubMed  Google Scholar 

  4. Levin B, Lieberman DA, McFarland B, et al. American Cancer Society Colorectal Cancer Advisory Group, US Multi-Society Task Force, American College of Radiology Colon Cancer Committee. Gastroenterology. 2008;5:1570–1595.

    Article  Google Scholar 

  5. Centers for Disease C, Prevention. Vital signs: colorectal cancer screening test use—United States, 2012. MMWR. 2013;62:881–888.

    Google Scholar 

  6. Surveillance E, End Results Program. SEER Stat Fact Sheets: Colon and Rectum Cancer: Centers for Disease Control; 2014. http://seer.cancer.gov/statfacts/html/colorect.html.

  7. Green BB, Wang CY, Anderson ML, et al. An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial. Ann Intern Med. 2013;158:301–311. PMCID: 3953144.

  8. National Center for Health Statistics. National Health Interview Survey (NHIS) public use data release: NHIS survey description. Hyattsville, MD: US Department of Health and Human Services, CDC, national Center for Health Statistics 2011; 2010. ftp://ftp.cdc.gov/pub/health_statistics/nchs/dataset_documentation/nhis/2010/srv.

  9. Hoang TV, Gor BJ, Liang J, Esparza A, et al. Asian American Health Needs Assessment, 2006 community report. Houston, TX: The University of Texas MD Anderson Cancer Center; 2006.

    Google Scholar 

  10. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150:1–8.

    Article  PubMed  Google Scholar 

  11. Degnan N, Patnick J, Von Karsa L, eds. International Agency for Research on Cancer. European Guidelines for Quality Assurance in Colorectal cancer Screening and Diagnosis. 1st edn. Belgium: European Union; 2010.

  12. Cancer Care Ontario. Colon cancer check 2010 program report. Cancer Care Ontario, Toronto Canada; 2012. www.cancercare.on.ca/coloscreening.

  13. Imperiale T, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–1297.

    Article  CAS  PubMed  Google Scholar 

  14. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2007;16:1935–1953.

    Article  CAS  PubMed  Google Scholar 

  15. Nielsen HJ, Jakobsen KV, Christensen IJ, Brunner N for the Danish Study Group on early Detection of Colorectal Cancer. Screening for colorectal cancer: possible improvements by risk assessment evaluation? Scan J Gastroenterol. 2011; 46:1283–1294.

  16. Sanduleanu S, le Clercq CM, Dekker E, et al. Definition and taxonomy of interval colorectal cancers: a proposal for standardising nomenclature. Gut. 2014. doi:10.1136/gutjnl-2014-307992.

  17. Tao S, Hundt S, Haug U, Brenner H. Sensitivity estimates of blood-based tests for colorectal cancer detection: impact of overrepresentation of advanced stage disease. Am J Gastroenterol. 2011;106:242–253.

    Article  PubMed  Google Scholar 

  18. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546–1558. PMCID: 3749880.

  19. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. PMCID: 4017867.

  20. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci. 2005;102:16368–16373.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massive parallel sequencing. Proc Natl Acad Sci. 2011;108:9350–9535.

    Article  Google Scholar 

  22. Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol. 2009;27:858–863.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Grutzmann R, Molnar B, Pilarsky C, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One. 2008;3:e3759.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Lofton-Day C, Model F, Devos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem.. 2008;54:414–423.

    Article  CAS  PubMed  Google Scholar 

  25. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–325.

    PubMed Central  CAS  PubMed  Google Scholar 

  26. Hofsli E, Sjursen W, Prestvik WS, et al. Identification of serum microRNA profiles in colon cancer. Br J Cancer. 2013;108:1712–1719.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Adamczyk B, Tharmalingam T, Rudd PM. Glycans as cancer biomarkers. Biochim Biophys Acta. 2012;1820:1347–1353.

    Article  CAS  PubMed  Google Scholar 

  28. Patwa TH, Zhao J, Anderson MA, Simeone DM, Lubman DM. Screening of glycosylation patterns in serum using natural glycoprotein microarrays and multi-lectin fluorescence detection. Anal Chem. 2006;78:6411–6421.

    Article  CAS  PubMed  Google Scholar 

  29. Yue T, Maupin KA, Fallon B, et al. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One. 2011;6:e29180. PMCID: 3248411.

  30. Zhao J, Patwa TH, Qiu W, et al. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. Journal of proteome research.. 2007;6:1864–1874.

    Article  CAS  PubMed  Google Scholar 

  31. Zhao J, Qiu W, Simeone DM, Lubman DM. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J Proteome Res. 2007;6:1126–1138.

    Article  CAS  PubMed  Google Scholar 

  32. Qiu Y, Patwa TH, Xu L, et al. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res. 2008;7:1693–1703.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Rho JH, Mead JR, Wright WS, et al. Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. J Proteomics. 2014;96:291–299.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Bresalier RS, Byrd JC, Tessler D, et al. A circulating ligand for galectin-3 is a haptoglobin-related glycoprotein elevated in individuals with colon cancer. Gastroenterology.. 2004;127:741–748.

    Article  CAS  PubMed  Google Scholar 

  35. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma Insulin-like growth factor and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev.. 2000;9:345–349.

    CAS  PubMed  Google Scholar 

  36. Giovannucci E, Pollak M, Platz EA, et al. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses’ Health Study. Growth Horm IGF Res. 2000;10:S30–S301.

    Article  PubMed  Google Scholar 

  37. Palmquist R, Stattin P, Rinaldi S, et al. Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: a prospective study in northern Sweden. Int J Cancer.. 2003;107:89–93.

    Article  Google Scholar 

  38. Cruz-Correa M, Cui H, Giardiello FM, et al. Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. Gastroenterology. 2004;126:964–970.

    Article  CAS  PubMed  Google Scholar 

  39. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 2002;62:6442–6446.

    CAS  PubMed  Google Scholar 

  40. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003;299:1753–1755.

    Article  CAS  PubMed  Google Scholar 

  41. Woodson K, Flood A, Green L, et al. Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women. J Natl Cancer Inst. 2004;96:407–410.

    Article  CAS  PubMed  Google Scholar 

  42. Narai S, Watanabe M, Hasegawa H, et al. Significance of Transforming growth factor beta 1 as a new tumor marker for colorectal cancer. Int J Cancer. 2002;97:508–511.

    Article  CAS  PubMed  Google Scholar 

  43. Broll R, Erdmann H, Duchrow M, et al. Vascular endothelial growth factor (VEGF)—a valuable serum tumour marker in patients with colorectal cancer? Eur J Surg Oncol.. 2001;27:37–42.

    Article  CAS  PubMed  Google Scholar 

  44. Takeda A, Shimada H, Imaseki H, et al. Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients : correlation with clinicopathological factors and tumor markers. Oncol Rep. 2000;7:333–338.

    CAS  PubMed  Google Scholar 

  45. Feldman AL, Alexander HR Jr, Bartlett DL, et al. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol. 2001;8:741–745.

    Article  CAS  PubMed  Google Scholar 

  46. Peeters CF, Thomas CM, Sweep FC, Span PN, Wobbes T, Ruers TM. Elevated serum endothelin-1 levels in patients with colorectal cancer; relevance for prognosis. Int J Biol Markers. 2000;15:288–293.

    CAS  PubMed  Google Scholar 

  47. Holten-Anderson MN, Christensen IJ, Nielsen HJ, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res. 2002;8:156–164.

    Google Scholar 

  48. Alexiou D, Karayiannakis AJ, Syrigos KN, et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer. 2001;37:2392–2397.

    Article  CAS  PubMed  Google Scholar 

  49. Ladd JJ, Busald T, Johnson MM, et al. Increased plasma levels of the APC-interacting protein MAPRE-1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prv Res. 2012;5:655–664.

    Article  CAS  Google Scholar 

  50. Scanlan MJ, Welt S, Gordon CM, et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 2002;62:4041–4047.

    CAS  PubMed  Google Scholar 

  51. Lu H, Goodell V, Disis ML. Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin Ther Targets. 2007;11:235–244.

    Article  CAS  PubMed  Google Scholar 

  52. Nam MJ, Madoz-Gurpide J, Wang H, et al. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics.. 2003;3:2108–2115.

    Article  CAS  PubMed  Google Scholar 

  53. Zaenker P, Ziman MR. Serologic autoantibodies as diagnostic cancer biomarkers—a review. Cancer Epidemiol Biomarkers Prev. 2013;22:2161–2181.

    Article  CAS  PubMed  Google Scholar 

  54. Reipert BM, Tanneberger S, Pannetta A, et al. Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer? Cancer Immunol Immunother. 2005;54:1038–1042.

    Article  CAS  PubMed  Google Scholar 

  55. He Y, Wu Y, Mou Z, et al. Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer. Proteomics Clin Appl. 2007;1:336–342.

    Article  CAS  PubMed  Google Scholar 

  56. Chen Y, Lin P, Qiu S, et al. Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol. 2007;30:1137–1144.

    CAS  PubMed  Google Scholar 

  57. Liu W, Wang P, Li Z, et al. Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer. Scand J Immunol. 2009;69:57–63.

    Article  CAS  PubMed  Google Scholar 

  58. Lim SH, Becker TM, Chua W, Ng WL, de Souza P, Spring KJ. Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer. J Clin Pathol. 2014;67:848–853.

    Article  CAS  PubMed  Google Scholar 

  59. Zhang Z, Nagrath S. Microfluidics and cancer: are we there yet? Biomed Microdevices. 2013;15:595–609. PMCID: 4017600.

  60. Murlidhar V, Zeinali M, Grabauskiene S, et al. A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells. Small. 2014;10:4895–4904.

    Article  CAS  PubMed  Google Scholar 

  61. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification and prediction: Standards for study design. J Natl cancer Instit. 2008;100:1432–1438.

    Article  CAS  Google Scholar 

  62. Surinova S, Sciess R, Huttenhein R, Ceciello F, Wollscheid B, Aebersold R. On the development of plasma protein biomarkers. J Proteome Res. 2011;10:5–16.

    Article  CAS  PubMed  Google Scholar 

  63. Toth K, Sipos F, Kalmar A, et al. Detection of methylated Sept9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLOS One. 2012;7:e46000.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Ladabaum U, Allen J, Wandell M, Ramsey S. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated Septin 9 DNA versus current strategies. Cancer Epidemiol Biomarkers Prev. 2013;22:1567–1576.

    Article  PubMed  Google Scholar 

  65. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other vesicles. Annu Rev Cell Biol. 2014;30:255–289.

    Article  CAS  Google Scholar 

  66. Tuck MK, Chan DW, Chia D, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009;8:113–117.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1466, Houston, TX, 77030, USA

    Robert S. Bresalier

  2. Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

    Scott Kopetz

  3. Department of Medical Oncology, The University of Michigan, Ann Arbor, MI, 48109, USA

    Dean E. Brenner

Authors
  1. Robert S. Bresalier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott Kopetz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dean E. Brenner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert S. Bresalier.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bresalier, R.S., Kopetz, S. & Brenner, D.E. Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?. Dig Dis Sci 60, 664–671 (2015). https://doi.org/10.1007/s10620-015-3575-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-015-3575-2

Keywords

Search

Navigation